What are the advantages of oral anticoagulant factor Xa or IIa inhibitors over traditional vitamin K antagonists (VKAs) in the treatment of deep venous thrombosis (DVT)?

Updated: Jun 05, 2019
  • Author: Kaushal (Kevin) Patel, MD; Chief Editor: Barry E Brenner, MD, PhD, FACEP  more...
  • Print

The new oral anticoagulant factor Xa or IIa inhibitors have numerous advantages over traditional VKAs, including rapid therapeutic effectiveness, ease of dosing, and lack of monitoring. Until recently, there were no approved drug-specific reversal agents for the NOACs.  A number of drugs are currently under development. [146, 147]

Due to the short half-life of FXa inhibitors, discontinuation of the drugs suffice in clinical situations in which there is time to await spontaneous clearance.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!